stockrow
Saturday 7 November 2026
Export CCCC’s income statement to Excel — free account
C4 Therapeutics, Inc.
CCCC Healthcare Biotechnology
C4 Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.9 million, up 1.02% from fiscal 2024.
- Revenue
- −24.6%
- EPS
- +63.6%
- Free cash flow
- +17.9%
Quarter to September 2026, against a year earlier
3.12
0.17
+5.76%
Follow CCCC
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.40 | 9.51 | 17.42 | 14.04 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.15) | (11.07) | (387.77) | (17.45) | |
P/B ratio |
0.62 | 1.42 | 2.47 | 1.99 | |
Price to Tangible BV |
0.62 | 1.42 | 2.47 | 1.99 | |
EV/Sales |
(1.98) | 3.29 | 10.72 | 8.26 | |
EV/EBITDA |
0.61 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.72 | (1.20) | (4.43) | (3.35) | |
EV/FCF |
0.72 | (1.20) | (4.40) | (3.33) | |
Quick Ratio |
7.60 | 8.75 | 5.29 | 4.99 | |
Current Ratio |
7.81 | 9.00 | 5.45 | 5.17 | |
Net Debt/EBITDA |
10.54 | 8.28 | 9.64 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.10 | 0.11 | 0.11 | 0.11 | |
Operating CF/Net income |
1.08 | 1.19 | 0.07 | 1.19 | |
Capex/Depreciation |
0.03 | 0.09 | (0.35) | — | |
Interest Coverage |
4.61 | 10.46 | 9.48 | — | |
Research and Development Expense of Revenue |
226.78% | 399.97% | 368.48% | 292.90% | |
Selling, General and Administrative Expense of Revenue |
83.32% | 151.67% | 129.39% | 97.56% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
36.37% | 43.42% | 45.72% | 35.19% | |
Graham Net Nets |
0.98 | 0.45 | 0.25 | 0.24 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(71.20%) | (45.25%) | (21.41%) | (21.62%) | |
Free Cash Flow Yield |
(62.72%) | (28.96%) | (13.99%) | (17.69%) | |
Revenue per Share |
0.13 | 0.05 | 0.05 | 0.06 | |
Operating CF per Share |
(0.27) | (0.24) | (0.01) | (0.19) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.27) | (0.24) | (0.01) | (0.19) | |
Cash per Share |
3.00 | 1.87 | 1.94 | 1.51 | |
Shareholders Equity per Share |
3.10 | 1.86 | 1.89 | 1.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.10 | 1.86 | 1.89 | 1.68 | |
Free Cash Flow |
(22.16) | (30.01) | (1.61) | (25.97) | |
Working Capital |
225.08 | 218.12 | 214.66 | 173.04 | |
Capital Expenditures |
(0.01) | (0.06) | (0.04) | — | |
Net Current Asset Value |
155.62 | 150.76 | 150.76 | 110.87 | |
EV/EBIT |
0.62 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.75 | 5.46 | 1.75 | 3.97 | |
Average Payables |
1.09 | 0.73 | 1.67 | 1.15 | |
Average Assets |
354.34 | 324.19 | 327.97 | 298.64 | |
Average Common Equity |
236.29 | 214.69 | 210.66 | 191.29 |
Columns are period end dates · fundamentals updated 5 Nov 2026